US Market In Pulmonx' Sights Nine Years After Zephyr First Failure

24 Oct 2017

Pulmonx is almost ready to submit the results of the pivotal LIBERATE trial of its Zephyr endobronchial valve to the US FDA. The data will support a premarket approval and the company hopes to bring the device, along with the Chartis patient-selection system, to the US market in 2018.

Pulmonx Corp. believes it is close to finally earning US FDA approval for its Zephyr endobronchial valve, nine years after the agency rejected it and almost 20 years since it was first developed.

The Zephyr is a small silicone-covered stent-valve installed in the lungs via a minimally invasive procedure to block airflow to...